68P A phase Ib study of lenvatinib + pembrolizumab (LEN + PEMBRO) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 116 follow-up analysis
Titel:
68P A phase Ib study of lenvatinib + pembrolizumab (LEN + PEMBRO) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 116 follow-up analysis
Auteur:
Kudo, M. Finn, R. Ikeda, M. Zhu, A. Sung, M. Baron, A. Okusaka, T. Kobayashi, M. Kumada, H. Kaneko, S. Pracht, M. Meyer, T. Nagao, S. Saito, K. Mody, K. Dubrovsky, L. Llovet, J.